240 related articles for article (PubMed ID: 35007301)
21. Cardioprotective effect of tamoxifen and raloxifene: Preventing proteoglycan synthesis by modulating non-canonical TGF-β signalling through NADPH oxidase and ERK phosphorylation.
Zarezade V; Mohammadtaghvaei N; Rashidi M; Babaahmadi-Rezaei H
Biochem Biophys Res Commun; 2023 Sep; 671():263-269. PubMed ID: 37307710
[TBL] [Abstract][Full Text] [Related]
22. Estrogen and selective estrogen receptor modulators exert neuroprotective effects and stimulate the expression of selective Alzheimer's disease indicator-1, a recently discovered antiapoptotic gene, in human neuroblast long-term cell cultures.
Benvenuti S; Luciani P; Vannelli GB; Gelmini S; Franceschi E; Serio M; Peri A
J Clin Endocrinol Metab; 2005 Mar; 90(3):1775-82. PubMed ID: 15585566
[TBL] [Abstract][Full Text] [Related]
23. The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1.
Lewis-Wambi JS; Kim H; Curpan R; Grigg R; Sarker MA; Jordan VC
Mol Pharmacol; 2011 Oct; 80(4):610-20. PubMed ID: 21737572
[TBL] [Abstract][Full Text] [Related]
24. Heat shock protein 22 (HSPB8) reduces the migration of hepatocellular carcinoma cells through the suppression of the phosphoinositide 3-kinase (PI3K)/AKT pathway.
Matsushima-Nishiwaki R; Toyoda H; Takamatsu R; Yasuda E; Okuda S; Maeda A; Kaneoka Y; Yoshimi N; Kumada T; Kozawa O
Biochim Biophys Acta Mol Basis Dis; 2017 Jun; 1863(6):1629-1639. PubMed ID: 28456666
[TBL] [Abstract][Full Text] [Related]
25. Raloxifene analogue LY117018 suppresses oxidative stress-induced endothelial cell apoptosis through activation of ERK1/2 signaling pathway.
Yu J; Eto M; Kozaki K; Akishita M; Okabe T; Ouchi Y
Eur J Pharmacol; 2008 Jul; 589(1-3):32-6. PubMed ID: 18541231
[TBL] [Abstract][Full Text] [Related]
26. Effect of estrogen on growth and apoptosis in esophageal adenocarcinoma cells.
Sukocheva OA; Wee C; Ansar A; Hussey DJ; Watson DI
Dis Esophagus; 2013 Aug; 26(6):628-35. PubMed ID: 23163347
[TBL] [Abstract][Full Text] [Related]
27. Effects of a combined treatment with tamoxifen and estrogen receptor β agonists on human breast cancer cell lines.
Lattrich C; Schüler S; Häring J; Skrzypczak M; Ortmann O; Treeck O
Arch Gynecol Obstet; 2014 Jan; 289(1):163-71. PubMed ID: 23907354
[TBL] [Abstract][Full Text] [Related]
28. GLP-1 reduces the migration of hepatocellular carcinoma cells via suppression of the stress-activated protein kinase/c-Jun N-terminal kinase pathway.
Yamada N; Matsushima-Nishiwaki R; Kobayashi K; Tachi J; Kozawa O
Arch Biochem Biophys; 2021 May; 703():108851. PubMed ID: 33771507
[TBL] [Abstract][Full Text] [Related]
29. The immune activity of selective estrogen receptor modulators is gene and macrophage subtype-specific yet converges on Il1b downregulation.
Sfogliarini C; Pepe G; Cesta CM; Allegretti M; Locati M; Vegeto E
Biomed Pharmacother; 2023 Sep; 165():115008. PubMed ID: 37442065
[TBL] [Abstract][Full Text] [Related]
30. Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen.
Zou A; Marschke KB; Arnold KE; Berger EM; Fitzgerald P; Mais DE; Allegretto EA
Mol Endocrinol; 1999 Mar; 13(3):418-30. PubMed ID: 10076999
[TBL] [Abstract][Full Text] [Related]
31. Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta.
Kumar A; Klinge CM; Goldstein RE
Int J Oncol; 2010 May; 36(5):1067-80. PubMed ID: 20372779
[TBL] [Abstract][Full Text] [Related]
32. Comparative effects of raloxifene, tamoxifen and estradiol on human osteoblasts in vitro: estrogen receptor dependent or independent pathways of raloxifene.
Miki Y; Suzuki T; Nagasaki S; Hata S; Akahira J; Sasano H
J Steroid Biochem Mol Biol; 2009 Feb; 113(3-5):281-9. PubMed ID: 19429434
[TBL] [Abstract][Full Text] [Related]
33. The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation.
Nalbandian G; Paharkova-Vatchkova V; Mao A; Nale S; Kovats S
J Immunol; 2005 Aug; 175(4):2666-75. PubMed ID: 16081843
[TBL] [Abstract][Full Text] [Related]
34. Non-classical estrogen receptors action on human dermal fibroblasts.
Tsui KH; Wang PH; Chen CK; Chen YJ; Chiou SH; Sung YJ; Li HY
Taiwan J Obstet Gynecol; 2011 Dec; 50(4):474-8. PubMed ID: 22212320
[TBL] [Abstract][Full Text] [Related]
35. SERMs attenuate estrogen-induced malignant transformation of human mammary epithelial cells by upregulating detoxification of oxidative metabolites.
Hemachandra LP; Patel H; Chandrasena RE; Choi J; Piyankarage SC; Wang S; Wang Y; Thayer EN; Scism RA; Michalsen BT; Xiong R; Siklos MI; Bolton JL; Thatcher GR
Cancer Prev Res (Phila); 2014 May; 7(5):505-15. PubMed ID: 24598415
[TBL] [Abstract][Full Text] [Related]
36. Differential SERM activation of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites.
Weatherman RV; Clegg NJ; Scanlan TS
Chem Biol; 2001 May; 8(5):427-36. PubMed ID: 11358690
[TBL] [Abstract][Full Text] [Related]
37. Pyk2 deficiency potentiates osteoblast differentiation and mineralizing activity in response to estrogen or raloxifene.
Posritong S; Hong JM; Eleniste PP; McIntyre PW; Wu JL; Himes ER; Patel V; Kacena MA; Bruzzaniti A
Mol Cell Endocrinol; 2018 Oct; 474():35-47. PubMed ID: 29428397
[TBL] [Abstract][Full Text] [Related]
38. Identification of selective estrogen receptor modulators by their gene expression fingerprints.
Zajchowski DA; Kauser K; Zhu D; Webster L; Aberle S; White FA; Liu HL; Humm R; MacRobbie J; Ponte P; Hegele-Hartung C; Knauthe R; Fritzemeier KH; Vergona R; Rubanyi GM
J Biol Chem; 2000 May; 275(21):15885-94. PubMed ID: 10748166
[TBL] [Abstract][Full Text] [Related]
39. In Vitro and In Silico Analyses of the Inhibition of Human Aldehyde Oxidase by Bazedoxifene, Lasofoxifene, and Structural Analogues.
Chen S; Austin-Muttitt K; Zhang LH; Mullins JGL; Lau AJ
J Pharmacol Exp Ther; 2019 Oct; 371(1):75-86. PubMed ID: 31289113
[TBL] [Abstract][Full Text] [Related]
40. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex.
Liu H; Lee ES; Deb Los Reyes A; Zapf JW; Jordan VC
Cancer Res; 2001 May; 61(9):3632-9. PubMed ID: 11325832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
